Evgen Pharma Share Discussion Threads

[timbo003] 19/1/2021 07:32

>>>MM

You are confusing the number of patients recruited with the numbers of patients completed.

We appear to be on track to complete recruitment of the first 100 patients some time around end of March, so 100 patients should have completed by end of April and DSMB's report should be end of April/beginning of May.

That is very good progress in my view and slightly ahead of expectations.

[nobbygnome] 19/1/2021 07:31

Just realised that the 56 are patients who,have been recruited not completed so you can add on another 28 days so end of August is my estimate for completion of the trial. Then there will be data analysis so we will get the results at the end of September most likely.

Essentially they are recruiting one patient a day so timbo's estimate was way closer that anyone else here.

[moneymunch] 19/1/2021 07:30

Don't talk wet, for one thing patients recruited for SFX-01's trial are from patients hospialised , displaying symptoms of ARDS and pneumonia, regardless of tesing positive for Covid-19.

[garth] 19/1/2021 07:27

You have to be signing up greater numbers at present - no good a flat rate of sign up because at some point, thankfully, there won't be the same volume of patients needing the treatment?

[peanut100] 19/1/2021 07:24

Let's not start that rubbish. 56 still better than 1.

[amaretto1] 19/1/2021 07:20

U seen VAL News

[nobbygnome] 19/1/2021 07:13

About the rate i would have expected. So 56 have been recruited in 8 weeks so to get 300 so at the current rate we are looking at about September for completion. I am sure recruitment will accelerate a bit so I guess we might be looking end of July at the earliest. There was one participant here who was suggesting February or was it March.....

[moneymunch] 19/1/2021 07:10

Yep, every chance of a February UPdate on DSMB's assessment on the first 100 patients. Gla ;-)

[amaretto1] 19/1/2021 07:07

Good progress !

[moneymunch] 19/1/2021 07:02

RNS Number : 0902M
Evgen Pharma PLC
19 January 2021


Evgen Pharma plc

("Evgen" or the "Company")



Update on patient recruitment in STAR-COVID 19 trial



Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that as of 18 January, a total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").



This Phase II/III randomised, placebo-controlled trial is sponsored by the University of Dundee and funded by the UK charity Life Arc. It will investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") in patients with community-acquired pneumonia from any infective agent and who have been or are being tested for suspected COVID-19. Patients may therefore present with COVID-19 or other respiratory diseases.



The trial design includes an assessment of safety and futility by a Data Safety and Monitoring Board who will review unblinded data on the first 100 patients treated. An announcement will be made when this point has been reached.



SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. Preclinical studies have shown that up-regulating the Nrf2 pathway has the potential to reduce the severity of ARDS, the progressive lung damage observed in COVID-19 and pneumonia patients, which can result in the need for invasive ventilation in an intensive care unit.



Dr Huw Jones, CEO of Evgen, commented: "We are pleased with the recruitment progress in this trial and would like to thank Professor James Chalmers and his colleagues at Dundee for their considerable efforts in a difficult clinical environment. We are greatly encouraged by recent academic papers which reinforce previous preclinical data showing the potential benefit to ARDS patients of up-regulating Nrf2 and hope that SFX-01 may be a valuable addition to the array of treatments that these seriously ill patients can receive. We look forward to further updating the market as we progress through this important trial.''

[wanobi] 18/1/2021 20:21

no problem ssb, my error, I have not checked your history, should have done so, apols,,,, I mistakenly thought I might be helping you with my charts,,, but I understand if you see things differently,,, I come in peace :-) and I have a large position in EVG :-) Cheers Wan :-)

[wanobi] 18/1/2021 20:13

aha, ok, maybe they are, I'll take them down ssb, cheers Wan :-)

I'll still be using them though :-) LOL

[amaretto1] 18/1/2021 20:07

Nothing wrong with chart ...It's trading between 10 --11Forming a good support ....An intraday movement wouldn't alter this fact.Just in case MM are tempting buyers on a daily.

[wanobi] 18/1/2021 19:56

. charts taken down :-)

[sideshowbull] 18/1/2021 19:44

I think I made a mistake with EVG, chart looked good until it didn't .


Sorry guys, can't get it right all the time.

BWTFDIK

[amaretto1] 18/1/2021 19:38

Nearly went in for more today .. but instead went long CEY ... saw a few chunky buys going in..Followed them 100 just before close.Results are tomorow, don't usually do this.... but 5 down days ...If the trade pays off, I'll add here !

[nobbygnome] 18/1/2021 19:28

Yes extremely disappointing. The sellers persist and buyers seem to have gone AWOL despite the fact the company looks completely undervalued.

I wonder how many more MM has to sell....😉

[amaretto1] 18/1/2021 19:26

Sellers are still here... unexpected

[moneymunch] 17/1/2021 20:24

Yep, for Valneva, not Valirx, unless I've missed something ??? ;-)

Ps news from Evg coming very soon imho...Gl :-)

[amaretto1] 17/1/2021 18:48

U guys seen the VAL News ... Could be seriously positive for VAL.